SCHEMBL14929137

SCHEMBL14929137

C[C@]1(COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O[C@@H](n2cnc3c(=O)[nH]c(N)nc32)[C@@H](O)C1O

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ FUT5 Q11128 1/20 0.55
▸ TGM2 P21980 1/20 0.55
▸ POLG P54098 1/20 0.53
▸ NT5E P21589 1/20 0.52
▸ KRAS P01116 2/20 0.52
▸ PNP P00491 1/20 0.51
▸ POLB P06746 1/20 0.51
▸ P2RY2 P41231 2/20 0.51
▸ P2RY4 P51582 1/20 0.51
▸ P2RY6 Q15077 1/20 0.51
▸ TAS1R3 Q7RTX0 1/20 0.48
▸ TAS1R1 Q7RTX1 1/20 0.48
▸ STING1 Q86WV6 2/20 0.47
▸ PDE3B Q13370 1/20 0.47
▸ PDE3A Q14432 1/20 0.47
▸ DCPS Q96C86 1/20 0.47
▸ P2RY1 P47900 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16368368 1.00 FUT5 (0.55) FUT5TGM2POLGNT5EKRAS
SCHEMBL16373872 1.00 FUT5 (0.55) FUT5TGM2POLGNT5EKRAS
SCHEMBL14946278 1.00 FUT5 (0.55) FUT5TGM2POLGNT5EKRAS
SCHEMBL18573812 1.00 FUT5 (0.55) FUT5TGM2POLGNT5EKRAS
SCHEMBL18573811 1.00 FUT5 (0.55) FUT5TGM2POLGNT5EKRAS
SCHEMBL16368124 0.92 FUT5 (0.52) FUT5TGM2POLGNT5EKRAS
SCHEMBL15075520 0.92 FUT5 (0.52) FUT5TGM2POLGNT5EKRAS
SCHEMBL15070747 0.92 FUT5 (0.52) FUT5TGM2POLGNT5EKRAS
SCHEMBL16367979 0.91 IMPDH2 (0.46) FUT5TGM2POLGP2RY2P2RY6
SCHEMBL19590349 0.89 TGM2 (0.55) FUT5TGM2POLGNT5EKRAS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170056528-A1 MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF MODERNATX, INC. 2017-03-02 — — US disclosed
US-20170056528-A1 MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF MODERNATX, INC. 2017-03-02 — — US disclosed
US-9428535-B2 Modified nucleosides, nucleotides, and nucleic acids, and uses thereof MODERNA THERAPEUTICS, INC. (US) 2016-08-30 — — US disclosed
US-9428535-B2 Modified nucleosides, nucleotides, and nucleic acids, and uses thereof MODERNA THERAPEUTICS, INC. (US) 2016-08-30 — — US disclosed
US-20130123481-A1 MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF modeRNA Therapeutics (US) 2013-05-16 — — US disclosed
US-20130115272-A1 MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF modeRNA Therapeutics (US) 2013-05-09 — — US disclosed
US-20130115272-A1 MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF modeRNA Therapeutics (US) 2013-05-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130123481-A1 MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF ADAR, NT5C3B, NSUN2 FUT5 351/4885TGM2 2181/4885POLG 349/4885
US-20170056528-A1 MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF ADAR, NT5C3B, NSUN2 FUT5 351/4885TGM2 2181/4885POLG 349/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback